Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 101–200 of 876
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 141
Role of PARP Inhibitors in Cancer Biology and Therapy
Davar, D., Beumer, J. H., Hamieh, L., & Tawbi, H. A.-H. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802002464 · Cited by 142
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M., O’Byrne, K. J., & Richard, D. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00086 · Cited by 121
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 129
Targeting triple negative breast cancer: Is p53 the answer?
Turner, N. H., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D’Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Sal, G. D., et al. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.001 · Cited by 136
Breunig, C., Pahl, J., Küblbeck, M., Miller, M., Antonelli, D., Erdem, N., Wirth, C., Will, R., Bott, A., Cerwenka, A., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.364 · Cited by 116
Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 130
Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned
Santa-Maria, C. A., & Gradishar, W. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1198 · Cited by 126
Molecular Pathways: Targeting PARP in Cancer Treatment
Do, K. T., & Chen, A. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0163 · Cited by 127
Connolly, R. M., Zhao, F., Miller, K. D., Lee, M.-J., Piekarz, R. L., Smith, K. L., Brown-Glaberman, U. A., Winn, J. S., Faller, B. A., Onitilo, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00944 · Cited by 125
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting, highlighting the importance of careful phase III study design.(16,17) E2112 did not meet its primary objective.”
BackgroundStefánsson, Ó. A., Jonasson, J. G., Ólafsdóttir, K., Hilmarsdóttir, H., Ólafsdóttir, G. H., Esteller, M., Jóhannsson, Ó. Þ., & Eyfjord, J. E. (2011) · Epigenetics · doi:10.4161/epi.6.5.15667 · Cited by 125
Lok, B. H., & Powell, S. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3150 · Cited by 104
Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
Stefánsson, Ó. A., & Esteller, M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.033 · Cited by 125
Systemic treatment strategies for triple-negative breast cancer
Yadav, B. S., Sharma, S. C., Chanana, P., & Jhamb, S. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.125 · Cited by 123
Personalizing health care: feasibility and future implications
Godman, B., Finlayson, A. E. T., Cheema, P. K., Zebedin-Brandl, E. M., Gutiérrez‐Ibarluzea, I., Jones, J., Malmström, R. E., Asola, E., Baumgärtel, C., Bennie, M., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-179 · Cited by 121
Palma, S. D., Simpson, R. H. W., Marchiò, C., Skálová, A., Ungari, M., Sandison, A., Whitaker, S. J., Parry, S., & Reis-Filho, J. S. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04252.x · Cited by 121
Papadimitriou, M., Mountzios, G., & PAPADIMITRIOU, C. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.010 · Cited by 119
Male BRCA mutation carriers: clinical characteristics and cancer spectrum
Ibrahim, M., Yadav, S., Ogunleye, F. N., & Zakalik, D. (2018) · BMC Cancer · doi:10.1186/s12885-018-4098-y · Cited by 119
Fostira, F., Tsitlaidou, M., PAPADIMITRIOU, C. A., Pertesi, M., Timotheadou, E. T., Stavropoulou, A. V., Glentis, S., Bournakis, E., Bobos, M., Pectasides, D. G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2021-9 · Cited by 118
The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment
Fornier, M. N., & Fumoleau, P. (2011) · The Breast Journal · doi:10.1111/j.1524-4741.2011.01175.x · Cited by 117
Groheux, D., Hindié, E., Giacchetti, S., Delord, M., Hamy, A., de Roquancourt, A., Vercellino, L., Bérenger, N., Marty, M. E., & Espié, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094045 · Cited by 117
Omics-based nanomedicine: The future of personalized oncology
Rosenblum, D., & Peer, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.029 · Cited by 117
Targeted therapy for triple‐negative breast cancer: Where are we?
Duffy, M. J., McGowan, P. M., & Crown, J. P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27632 · Cited by 117
18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer
Haug, A. R., Donfack, B. P. T., Trumm, C. G., Zech, C. J., Michl, M., Laubender, R. P., Uebleis, C., Bartenstein, P., Heinemann, V., & Hacker, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096230 · Cited by 114
PARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 114
Therapies for triple negative breast cancer
Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 114
Li, X., Jeon, Y., Kwon, N., Park, J.-G., Guo, T., Kim, H., Huang, J., Lee, D., & Yoon, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120430 · Cited by 112
miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
Mathe, A., Scott, R. J., & Avery‐Kiejda, K. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226090 · Cited by 111
Pitroda, S. P., Pashtan, I. M., Logan, H. L., Budke, B., Darga, T. E., Weichselbaum, R. R., & Connell, P. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008291 · Cited by 107
Liu, H., Qiu, W., Sun, T., Wang, L., Du, C., Hu, Y., Liu, W., Feng, F., Yao, C., & Sun, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.019 · Cited by 107
Failures in Phase III: Causes and Consequences
Seruga, B., Ocana, A., Amir, E., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0124 · Cited by 88
Jardim, D. L. F., Groves, E. S., Breitfeld, P. P., & Kurzrock, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.009 · Cited by 106
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
Javle, M., & Curtin, N. J. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011417039 · Cited by 92
Wang, L., Wang, M., Zhou, B., Zhou, F., Murray, C. K., Towner, R. A., Smith, N., Saunders, D., Xie, G., & Chen, W. R. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00630c · Cited by 102
Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies
Jain, R. K., Lee, J. J., Ng, C. S., Hong, D. S., Gong, J., Naing, A., Wheler, J. J., & Kurzrock, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4752 · Cited by 102
Biologic markers determine both the risk and the timing of recurrence in breast cancer
Esserman, L. J., Moore, D. H., Tsing, P., Chu, P., Yau, C. S. F., Ozanne, E. M., Chung, R., Tandon, V. J., Park, J. W., Baehner, F. L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1564-5 · Cited by 105
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation
van Vuurden, D. G., Hulleman, E., Meijer, O. L. M., Wedekind, L. E., Kool, M., Witt, H., Vandertop, W. P., Würdinger, T., Noske, D. P., Kaspers, G. J. L., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.362 · Cited by 103
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 100
Owonikoko, T. K., Zhang, G., Deng, X., Rossi, M. R., Switchenko, J. M., Doho, G., Chen, Z., Kim, S., Strychor, S., Christner, S. M., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.317 · Cited by 100
Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury
Mukhopadhyay, P., Horváth, B., Kechrid, M., Tanchian, G., Rajesh, M., Naura, A. S., Boulares, A. H., & Pacher, P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.08.006 · Cited by 94
Triple-negative breast cancer: are we making headway at least?
Arnedos, M., Bihan, C., Delaloge, S., & André, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012444711 · Cited by 101
Grignani, G., D’Ambrosio, L., Pignochino, Y., Palmerini, E., Zucchetti, M., Boccone, P., Aliberti, S., Stacchiotti, S., Bertulli, R., Piana, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30438-8 · Cited by 98
Online Tool to Guide Decisions forBRCA1/2Mutation Carriers
Kurian, A. W., Muñoz, D. F., Rust, P., Schackmann, E. A., Smith, M. H., Clarke, L. D., Mills, M. A., & Plevritis, S. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6060 · Cited by 97
The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma
Oca, R. M. D., Gurard‐Levin, Z. A., Berger, F., Rehman, H., Martel, E., Corpet, A., de Koning, L., Vassias, I., Wilson, L. O. W., Meseure, D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.11.002 · Cited by 97
Xu, Y., Diao, L., Chen, Y., Liu, Y., Wang, C. Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt011 · Cited by 97
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Chuang, H.-C., Kapuriya, N., Kulp, S. K., Chen, C.-S., & Shapiro, C. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2106-5 · Cited by 90
Schüler, M., Awada, A. H., Harter, P., Canon, J. L., Possinger, K., Schmidt, M., Grève, J. D., Neven, P., Dirix, L. Y., Jonat, W., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2126-1 · Cited by 96
von Minckwitz, G., Müller, B. M., Loibl, S., Budczies, J., Hanusch, C. A., Darb‐Esfahani, S., Hilfrich, J., Weiss, E., Huober, J., Blohmer, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9079 · Cited by 98
The role of PARP1 in the DNA damage response and its application in tumor therapy
Wang, Z., Wang, F., Tang, T.-S., & Guo, C. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0197-3 · Cited by 95
Stem cells in breast tumours: Are they ready for the clinic?
Ablett, M. P., Singh, J. K., & Clarke, R. B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.019 · Cited by 94
Kuo, W.-Y., Hwu, L., Wu, C.-Y., Lee, J.-S., Chang, C., & Liu, R.-S. (2017) · Theranostics · doi:10.7150/thno.16827 · Cited by 94
Inherited Mutations in Breast Cancer Genes—Risk and Response
Shuen, A. Y., & Foulkes, W. D. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9213-5 · Cited by 95
Nowsheen, S., Bonner, J. A., & Yang, E. S. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.084 · Cited by 93
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer
Siroy, A. E., Abdul‐Karim, F. W., Miedler, J. D., Fong, N., Fu, P., Gilmore, H. L., & Baar, J. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.04.010 · Cited by 92
Cancer treatment according to BRCA1 and BRCA2 mutations
Maxwell, K. N., & Domchek, S. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.123 · Cited by 93
Breast Cancer Chemoprevention: Old and New Approaches
Cazzaniga, M., & Bonanni, B. (2012) · BioMed Research International · doi:10.1155/2012/985620 · Cited by 90
Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
Gucalp, A., & Traina, T. A. (2011) · Chemotherapy Research and Practice · doi:10.1155/2011/696208 · Cited by 89
Ly, M., Antoine, M., Dembélé, A. K., Lévy, P., Rodenas, A., Touré, B. A., Badiaga, Y., Dembélé, B. K., Bagayogo, D. C., Diallo, Y., et al. (2012) · Oncology · doi:10.1159/000341541 · Cited by 88
Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection
Peng, G., Dai, H., Zhang, W., Hsieh, H.-J., Pan, M.-R., Park, Y.-Y., Tsai, R. Y.-L., Bedrosian, I., Lee, J.-S., Ira, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3152 · Cited by 73
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
Evans, D. G., Howell, A., Ward, D., Lalloo, F. I., Jones, J. L., & Eccles, D. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100006 · Cited by 87
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
Zhang, J., Wang, Z., Hu, X., Wang, B., Wang, L., Yang, W., Liu, Y., Liu, G., Di, G., Hu, Z., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28966 · Cited by 86
Zeng, X., Shi, G., He, Q., & Zhu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00268-9 · Cited by 85
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines
Barnabas, N., & Cohen, D. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/872743 · Cited by 86
Defective homologous recombination in human cancers
Cerbinskaite, A., Mukhopadhyay, A., Plummer, E. R., Curtin, N. J., & Edmondson, R. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.015 · Cited by 86
Choi, Y. E., Pan, Y., Park, E., Konstantinopoulos, P. A., De, S., D’Andrea, A. D., & Chowdhury, D. (2014) · eLife · doi:10.7554/elife.02445 · Cited by 85
Novel therapeutic strategies in the treatment of triple-negative breast cancer
Oualla, K., El‐Zawahry, H. M., Arun, B., Reuben, J. M., Woodward, W. A., El-Din, H. G., Lim, B., Mellas, N., Ueno, N. T., & Fouad, T. M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017711380 · Cited by 85
Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
McLellan, J. L., O’Neil, N. J., Barrett, I. J., Ferree, E. J., van Pel, D. M., Ushey, K., Sipahimalani, P., Bryan, J., Rose, A. M., & Hieter, P. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002574 · Cited by 84
Molecular heterogeneity of triple-negative breast cancer and its clinical implications
Irshad, S., Ellis, P., & Tutt, A. N. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834bf8ae · Cited by 83
BRCA Mutation Testing in Determining Breast Cancer Therapy
Smith, K. L., & Isaacs, C. J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318238f579 · Cited by 82
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
Turner, N. C., & Tutt, A. N. J. (2012) · Breast Cancer Research · doi:10.1186/bcr3332 · Cited by 82
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
Saraiva, D. P., Cabral, M. G., Jacinto, A., & Braga, S. A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000208 · Cited by 81
18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
Ulaner, G. A., Castillo, R., Goldman, D. A., Wills, J., Riedl, C. C., Pinker, K., Jochelson, M. S., & Gönen, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3402-9 · Cited by 80
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Papa, A., Caruso, D., Strudel, M., Tomao, F., & Tomao, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1027-1 · Cited by 80
Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides
Cant, A. A., Bhalla, R., Pimlott, S. L., & Sutherland, A. J. (2012) · Chemical Communications · doi:10.1039/c2cc30956d · Cited by 79
BRCAness: a deeper insight into basal-like breast tumors
Summa, S. D., Pinto, R., Sambiasi, D., Petriella, D., Paradiso, V., Paradiso, A., & Tommasi, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt306 · Cited by 80
Hirai, T., Shirai, H., Fujimori, H., Okayasu, R., Sasai, K., & Masutani, M. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02268.x · Cited by 68
Chen, Y., Yao, Z., Liu, P., Hu, Q., Huang, Y. X., Ping, L., Zhang, F., Tang, H., Wan, T., Ping, Y., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.01.050 · Cited by 77
Targeted therapy in brain metastasis
Soffietti, R., Trevisan, E., & Rudà, R. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283571a1c · Cited by 77
Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents
Zhao, J., & Feng, S. (2015) · Nanomedicine · doi:10.2217/nnm.15.61 · Cited by 75
Forero, A., Varley, K. E., Abramson, V. G., Li, Y., Vaklavas, C., Lin, N., Liu, M., Rugo, H. S., Nanda, R., Storniolo, A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2780 · Cited by 75
Targeting triple negative breast cancer with histone deacetylase inhibitors
Fedele, P., Orlando, L., & Cinieri, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1386172 · Cited by 75
Targeting the DNA damage response in oncology: past, present and future perspectives
Basu, B., Yap, T. A., Molife, L. R., & Bono, J. S. D. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835280c6 · Cited by 77
Time for more optimism in metastatic breast cancer?
Senkus, E., Cardoso, F., & Pagani, O. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.015 · Cited by 75
Atkinson, R. L., Yang, W. T., Rosen, D. G., Landis, M. D., Wong, H. H., Lewis, M. T., Creighton, C. J., Sexton, K. R., Hilsenbeck, S. G., Şahin, A. A., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3471 · Cited by 74
Multistage Vectored siRNA Targeting Ataxia‐Telangiectasia Mutated for Breast Cancer Therapy
Xu, R., Huang, Y., Mai, J., Zhang, G., Guo, X., Xia, X., Koay, E. J., Qin, G., Erm, D. R., Li, Q., et al. (2013) · Small · doi:10.1002/smll.201201510 · Cited by 73
Meng, Q., Meng, J., Ran, W., Wang, J., Zhai, Y., Zhang, P., & Li, Y. (2018) · ACS Nano · doi:10.1021/acsnano.7b09210 · Cited by 72
Chornenkyy, Y., Agnihotri, S., Yu, M., Buczkowicz, P., Rakopoulos, P., Golbourn, B. J., Garzia, L., Siddaway, R., Leung, S., Rutka, J. T., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0282 · Cited by 72
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer
Liu, Y., Zhang, Y., Zhao, Y., Gao, D., Xing, J., & Liu, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.5169 · Cited by 72
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 72
Liu, A., Qu, H., Gong, W., Xiang, J., Yang, M., & Zhang, W. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28747 · Cited by 71
Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies
Damaskos, C., Garmpi, A., Nikolettos, K., Vavourakis, M., Diamantis, E., Patsouras, A., Farmaki, P., Nonni, A., Dimitroulis, D., Mantas, D., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13722 · Cited by 71
Cancer stem cells, microRNAs, and therapeutic strategies including natural products
Vira, D., Basak, S. K., Veena, M. S., Wang, M. B., Batra, R. K., & Srivatsan, E. S. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9382-8 · Cited by 71
Liu, M., Ma, W., Zhao, D., Li, J., Li, Q., Liu, Y., Hao, L., & Lin, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c07297 · Cited by 69
Anders, C. K., Deal, A. M., Abramson, V. G., Liu, M., Storniolo, A. M., Carpenter, J. T., Puhalla, S., Nanda, R., Melhem‐Bertrandt, A., Lin, N., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3039-y · Cited by 69
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 70
Molecular Heterogeneity of Triple-Negative Breast Cancer
Abramson, V. G., & Mayer, I. A. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0152-1 · Cited by 69
Progress in targeted therapy for breast cancer
Ju, J., Zhu, A., & Yuan, P. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2018.04.002 · Cited by 68
Zakaria, Z., Zulkifle, M. F., Hasan, W. A. N. W., Azhari, A. K., Raub, S. H. A., Eswaran, J., Soundararajan, M., & Husain, S. N. A. S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214611 · Cited by 67
Differential Chemotherapeutic Sensitivity for Breast Tumors With “BRCAness”: A Review
Chalasani, P., & Livingston, R. B. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0039 · Cited by 70
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.